Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.

PHASE3CompletedINTERVENTIONAL
Enrollment

397

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Malaria
Interventions
DRUG

Azithromycin plus Chloroquine

Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)

DRUG

Mefloquine

Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0

Trial Locations (8)

40100

Pfizer Investigational Site, Kisumu

01

Pfizer Investigational Site, Ouagadougou

Unknown

Pfizer Investigational Site, Nouna

Pfizer Investigational Site, Navrongo

Pfizer Investigational Site, Bamako

Pfizer Investigational Site, Bamako

Pfizer Investigational Site, Senegal

Pfizer Investigational Site, Ndola

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00367653 - Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria. | Biotech Hunter | Biotech Hunter